Stada Arzneimittel AG - Strategic SWOT Analysis Review

Stada Arzneimittel AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company's key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

• Business description - A detailed description of the company's operations and business divisions.
• Corporate strategy - The publisher's summarization of the company's business strategy.
• SWOT analysis - A detailed analysis of the company's strengths, weakness, opportunities and threats.
• Company history - Progression of key events associated with the company.
• Major products and services - A list of major products, services and brands of the company.
• Key competitors - A list of key competitors to the company.
• Key employees - A list of the key executives of the company.
• Executive biographies - A brief summary of the executives' employment history.
• Key operational heads - A list of personnel heading key departments/functions.
• Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

Stada Arzneimittel AG (STADA), a subsidiary of Nidda Healthcare GmbH, is a manufacturer of low-cost generics and branded over-the-counter products. The company develops and markets drugs with off-patent active pharmaceutical ingredients, particularly, which are free from commercial property rights. It offers portfolio of products in various therapeutic categories including pain, women's health, cardiovascular conditions and diabetes. Few of its major generic products include including Tilidin Naloxon, Atorvastatin and Epoetin zeta. Its major branded products include APO-Go, Grippostad, Snup and Fultium. The company operates across Germany, Central Europe, CIS/Eastern Europe and Asia-Pacific. STADA is headquartered in Bad Vilbel, Germany.

Stada Arzneimittel AG Key Recent Developments

Jun 09, 2022: STADA and Alvotech broaden European patients' options by launching Hukyndra high-concentration, citrate-free adalimumab
Jan 19, 2022: STADA expands production network with EUR50m project in Romania
Jun 29, 2021: STADA to acquire 16 consumer healthcare brands from Sanofi

Reasons to Buy

• Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
• Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services and business strategy.
• Understand and respond to your competitors' business structure and strategies with the publisher's detailed SWOT analysis. In this, the company's core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
• Examine potential investment and acquisition targets with this report's detailed insight into the company's strategic, business and operational performance.

Note: Some sections may be missing if data is unavailable for the company.